Editas Medicine Inc expected to post a loss of 75 cents a share - Earnings Preview

Reuters

2024-10-30

* Editas Medicine Inc is expected to show a fall in quarterly revenue when it reports results on November 1 (estimated) for the period ending September 30 2024

* The Cambridge Massachusetts-based company is expected to report a 57.9% decrease in revenue to $2.245 million from $5.34 million a year ago, according to the mean estimate from 14 analysts, based on LSEG data.

* LSEG's mean analyst estimate for Editas Medicine Inc is for a loss of 75 cents per share.

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 9 "hold" and no "sell" or "strong sell."

* The mean earnings estimate of analysts was unchanged in the last three months.

* Wall Street's median 12-month price target for Editas Medicine Inc is $10.00, above its last closing price of $3.11.

Previous quarterly performance (using preferred earnings measure in US dollars).

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Jun. 30 2024 -0.73 -0.70 -0.82 Missed -16.6

Mar. 31 2024 -0.66 -0.66 -0.76 Missed -14.3

Dec. 31 2023 -0.60 -0.54 -0.23 Beat 57.6

Sep. 30 2023 -0.56 -0.57 -0.55 Beat 3.2

Jun. -0.76 -0.76 -0.56 Beat 26.6

30 2023

Mar. 31 2023 -0.78 -0.78 -0.71 Beat 9.4

Dec. 31 2022 -0.80 -0.80 -0.88 Missed -9.7

Jan. 1 0001 -0.83 -0.87 -0.81 Beat 6.8

This summary was machine generated October 30 at 13:26 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2479678852"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2479678852\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2479678852?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-30 21:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479678852","market":"us","top_or_hot":-1,"title":"Editas Medicine Inc    expected to post a loss of 75 cents a share - Earnings Preview","media":"Reuters","content":"<html><body><p>* Editas Medicine Inc     is expected to show a fall in quarterly revenue when it reports  results on November 1 (estimated) for the period ending September 30 2024</p><p>   * The Cambridge Massachusetts-based  company is expected to report a 57.9% decrease in revenue to $2.245 million from $5.34 million a year ago, according to the mean estimate from 14 analysts, based on LSEG data.</p><p>   * LSEG's mean analyst estimate for Editas Medicine Inc is for a loss of 75 cents per share. </p><p>   * The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 10 \"strong buy\" or \"buy,\" 9 \"hold\" and no \"sell\" or \"strong sell.\"  </p><p>   * The mean earnings estimate of analysts was unchanged in the last three months. </p><p>   * Wall Street's median 12-month price target for Editas Medicine Inc is $10.00, above its last closing price of $3.11. </p><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><p>QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI</p><p>ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %</p><p>              E®                               MISSED  </p><p>Jun. 30 2024  -0.73       -0.70      -0.82     Missed  -16.6</p><p>Mar. 31 2024  -0.66       -0.66      -0.76     Missed  -14.3</p><p>Dec. 31 2023  -0.60       -0.54      -0.23     Beat    57.6</p><p>Sep. 30 2023  -0.56       -0.57      -0.55     Beat    3.2</p><p>Jun.        -0.76       -0.76      -0.56     Beat    26.6</p><p>30 2023                                                </p><p>Mar. 31 2023  -0.78       -0.78      -0.71     Beat    9.4</p><p>Dec. 31 2022  -0.80       -0.80      -0.88     Missed  -9.7</p><p>Jan. 1 0001   -0.83       -0.87      -0.81     Beat    6.8</p><p>This summary was machine generated October 30 at 13:26 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Editas Medicine Inc    expected to post a loss of 75 cents a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEditas Medicine Inc    expected to post a loss of 75 cents a share - Earnings Preview\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2024-10-30 21:27</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p>* Editas Medicine Inc     is expected to show a fall in quarterly revenue when it reports  results on November 1 (estimated) for the period ending September 30 2024</p><p>   * The Cambridge Massachusetts-based  company is expected to report a 57.9% decrease in revenue to $2.245 million from $5.34 million a year ago, according to the mean estimate from 14 analysts, based on LSEG data.</p><p>   * LSEG's mean analyst estimate for Editas Medicine Inc is for a loss of 75 cents per share. </p><p>   * The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 10 \"strong buy\" or \"buy,\" 9 \"hold\" and no \"sell\" or \"strong sell.\"  </p><p>   * The mean earnings estimate of analysts was unchanged in the last three months. </p><p>   * Wall Street's median 12-month price target for Editas Medicine Inc is $10.00, above its last closing price of $3.11. </p><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><p>QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI</p><p>ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %</p><p>              E®                               MISSED  </p><p>Jun. 30 2024  -0.73       -0.70      -0.82     Missed  -16.6</p><p>Mar. 31 2024  -0.66       -0.66      -0.76     Missed  -14.3</p><p>Dec. 31 2023  -0.60       -0.54      -0.23     Beat    57.6</p><p>Sep. 30 2023  -0.56       -0.57      -0.55     Beat    3.2</p><p>Jun.        -0.76       -0.76      -0.56     Beat    26.6</p><p>30 2023                                                </p><p>Mar. 31 2023  -0.78       -0.78      -0.71     Beat    9.4</p><p>Dec. 31 2022  -0.80       -0.80      -0.88     Missed  -9.7</p><p>Jan. 1 0001   -0.83       -0.87      -0.81     Beat    6.8</p><p>This summary was machine generated October 30 at 13:26 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EDIT","symbol_name":"Editas Medicine, Inc.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2479678852","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479678852","pubTimestamp":1730294831,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"* Editas Medicine Inc     is expected to show a fall in quarterly revenue when it reports  results on November 1 (estimated) for the period ending September 30 2024   * The Cambridge Massachusetts-bas","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"EDIT":"Editas Medicine, Inc."},"translate_title":"Editas Medicine Inc预计每股亏损75美分-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EDIT":1},"content_text":"* Editas Medicine Inc     is expected to show a fall in quarterly revenue when it reports  results on November 1 (estimated) for the period ending September 30 2024   * The Cambridge Massachusetts-based  company is expected to report a 57.9% decrease in revenue to $2.245 million from $5.34 million a year ago, according to the mean estimate from 14 analysts, based on LSEG data.   * LSEG's mean analyst estimate for Editas Medicine Inc is for a loss of 75 cents per share.    * The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 10 \"strong buy\" or \"buy,\" 9 \"hold\" and no \"sell\" or \"strong sell.\"     * The mean earnings estimate of analysts was unchanged in the last three months.    * Wall Street's median 12-month price target for Editas Medicine Inc is $10.00, above its last closing price of $3.11. Previous quarterly performance (using preferred earnings measure in US dollars). QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRIENDING        ARTESTIMAT  ESTIMATE             MET,    SE %              E®                               MISSED  Jun. 30 2024  -0.73       -0.70      -0.82     Missed  -16.6Mar. 31 2024  -0.66       -0.66      -0.76     Missed  -14.3Dec. 31 2023  -0.60       -0.54      -0.23     Beat    57.6Sep. 30 2023  -0.56       -0.57      -0.55     Beat    3.2Jun.        -0.76       -0.76      -0.56     Beat    26.630 2023                                                Mar. 31 2023  -0.78       -0.78      -0.71     Beat    9.4Dec. 31 2022  -0.80       -0.80      -0.88     Missed  -9.7Jan. 1 0001   -0.83       -0.87      -0.81     Beat    6.8This summary was machine generated October 30 at 13:26 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"preview","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}